FDA approves Jardiance to reduce cardiovascular death in adults with type 2 diabetes

["U.S. Food & Drug Administration (FDA)" <fda@xxxxxxxxxxxxxxxxxxxxxxx>]

Title: FDA approves Jardiance to reduce cardiovascular death in adults with type 2 diabetes

View as webpage 

News Release

For Immediate Release: Dec. 2, 2016
Media Inquiries: Theresa Eisenman, 301-796-2969, theresa.eisenman@xxxxxxxxxxx
Consumer Inquiries: 888-INFO-FDA

FDA approves Jardiance to reduce cardiovascular death in adults with type 2 diabetes

SubtitleStudy links Jardiance to improved survival in patients with type 2 diabetes with cardiovascular disease

The U.S. Food and Drug Administration today approved a new indication for Jardiance (empagliflozin) to reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and cardiovascular disease.

Read more. 

###

---

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency is also responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

---

Subscriber Services:
Manage Preferences  |  Unsubscribe  |  Help with this service

Stay Connected:

---

This email was sent to list-fda@xxxxxxxxxxx using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 1-888-INFO-FDA (1-888-463-6332)